Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video) - 2I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works.
- 3Daily Briefing: A bad flu season gets worse
- 4Figure out How to Adjust Your Handshake to Various Societies
- 5Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- Single women risk rape and exploitation in search for better life in Europe
- Reviving Your Home with Nutritious Indoor Plants
- Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- EU waters down plans to end new petrol and diesel car sales by 2035
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- Grass Care Administrations for a Wonderful, Sound Yard
- Russia accidentally destroys its only way of sending astronauts to space
- Germany and trade unions kick off tough public-sector wage talks
